AM 114

Drug Profile

AM 114

Latest Information Update: 07 Sep 2006

Price : $50

At a glance

  • Originator Amura; Micron Research
  • Class Antibacterials; Oxapenems
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 25 Aug 2006 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
  • 31 Dec 2002 Data presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2002) have been added to the Bacterial Infections pharmacodynamics section
  • 16 Jul 2002 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top